Long-term safety and effectiveness of romiplostim for chronic idiopathic thrombocytopenic purpura in real-world settings

Long-term safety and effectiveness of romiplostim for chronic idiopathic thrombocytopenic purpura in real-world settings - Long-term safety and effectiveness of romiplostim for chronic idiopathic thrombocytopenic purpura in real-world settings

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047864

Enrollment

700

Registered

2022-06-01

Start date

2011-04-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic idiopathic thrombocytopenic purpura(chronic ITP)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who were treated with Romiplate for s.c. injection. Patients who were treated with Romiplate for diseases other than chronic ITP were also included in this survey.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Safety assessment: 1. Occurrence of ADRs / infectations (e.g., types and incidence) 2. Identifying factors that may affect the safety 3. Occurrence of serious adverse events 4. Examining primary investigation items Efficacy assessment: 1. Transition of platelet count 2. Identifying factors that may affect transition of platelet count	—

Countries

Japan

Contacts

Public ContactYukie Tsuji

Kyowa Kirin Co., Ltd. Pharmacovigilance Department

pmsrptitp.ve@kyowakirin.com03-5205-7200

Outcome results